4-Ethyl-pyrido-<3,2-d>-pyrimidin | 51675-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 4-Ethyl-pyrido-<3,2-d>-pyrimidin
• 英文别名: 4-ethyl-pyrido[3,2-d]pyrimidine；4-Ethylpyrido[3,2-d]pyrimidine
• CAS: 51675-06-0
• 化学式: C₉H₉N₃
• 分子量: 159.191
• InChiKey: VPNIHSYSUPNSQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLIZINONE UTILISÉS COMME INHIBITEURS DE PI3K
  申请人：LUPIN LTD

  公开号：WO2016001855A1

  公开（公告）日：2016-01-07

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1 - R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.

  本发明揭示了公式(I)的化合物及其互变异构体、立体异构体和药学上可接受的盐，其中R1-R4和n如规范所定义，包括一种化合物、互变异构体、立体异构体或其盐的制药组合物，以及治疗或预防疾病或障碍（例如癌症），该疾病或障碍可通过抑制受体内的PI3K酶来进行治疗或预防的方法。
• Pteridine dione monocarboxylate transporter inhibitors
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10328078B2

  公开（公告）日：2019-06-25

  The invention provides compounds effective as inhibitors of monocarboxylate transporters such as MCT1 and MCT4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on MCT1, MCT4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type II diabetes.

  本发明提供了对单羧酸盐转运体（如 MCT1 和 MCT4）具有抑制作用的化合物，这些化合物可用于治疗医学上需要用对 MCT1、MCT4 或两者均有抑制作用的化合物来治疗的病症。 本发明的化合物具有抗肿瘤、抗糖尿病、抗炎或免疫抑制的药理作用，可有效治疗癌症和 II 型糖尿病。
• Heterocyclic compounds as immunomodulators
  申请人：Incyte Corporation

  公开号：US11339149B2

  公开（公告）日：2022-05-24

  Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

  本发明公开了式（I）化合物、将这些化合物用作免疫调节剂的方法以及包含这些化合物的药物组合物。这些化合物可用于治疗、预防或改善癌症或感染等疾病或紊乱。
• C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170114065A1

  公开（公告）日：2017-04-27

  In its many embodiments, the present invention provides certain C2-carbocyclic iminothiazine dioxide compounds, including compounds Formula (I); or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R 1 , R 2 , ring A, R A , m, ring B, RB, n, ring C, R C and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
• PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS
  申请人：The Scripps Research Institute

  公开号：US20190282582A1

  公开（公告）日：2019-09-19

  The invention provides compounds effective as inhibitors of monocarboxylate transporters such as MCT1 and MCT4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on MCT1, MCT4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type II diabetes.